India exhibits a sole empowerment when it comes to coronavirus vaccinesWednesday March 3, 2021 at 10:49 pm
On Monday, the Chief Scientist of the World Health Organization, Soumya Swaminathan has stated that India has proved itself to be a global manufacturer and an innovator in regard to coronavirus vaccines.
While giving a speech at the Global Bio-India 2021, she held the opinion that as the cases are in an upward direction, especially in countries such as Europe and America, the fight against this fatal virus has become very critical. She added that due to the different variants of the virus, many uncertainties are cropping up.
She further noted, “India has shown the capacity to be a manufacturer at the global scale and also be an innovator when it came to vaccine development. There is a huge amount of scope to study the impact of vaccines, which needs to be thought – through by a very coordinated approach”.
In India, 30 vaccines are at different stages of the trial. The Serum Institute of India is manufacturing Covaxin, which is being indigenously developed by Biotech, and Covishield, which is being developed by Oxford- AstraZeneca, and are both in use in the country.
The vaccine candidates of Zydus Cadila and Sputnik V of Russia has reached phase 3 of the human clinical trials. Reddy’s Laboratories in India is manufacturing Sputnik V and it has initiated the process for Emergency Use Authorisation (EUA) with the Drugs Controller General of India (DCGI). Numerous nations have already received vaccines from India while some others have given their orders.
A member (Health) of NITI Aayog, Vinod Paul, has stated that the rate at which the solution for the pandemic is being reached is really noteworthy. The development of the vaccines points to the fact that how within a limited time scientific mobilization can be initiated.
He further added that the global recognition of the manufacturing sector in connection to Covid-19 vaccine was path-breaking and a concern to be really proud of. We have realized that we possess the potential to deliver in times of crisis, as we have done for the distribution of vaccine.